Diacerein is a prodrug which is metabolized to rhein. It is currently approved in France for the treatment of osteoarthritis although the use of diacerein is restricted due to the side effects including severe diarrhea . Diacerein is under investigation for the treatment of Insulin Resistance, Diabetes Mellitus (Type 2), and Diabetes-Related Complications.
For the treatment of osteoarthritis affecting the hip or knee .
Juree Rawdmanee, Sukhumvit, Bangkok, Thailand
Faculty of medicine, Chiangmai University, Chiangmai, Thailand
Kuljinder Singh, Amritsar, Punjab, India
Seoul National University Hospital, Seoul, Korea, Republic of
Hôpital Nord, Amiens, France
Hôpital Ambroise Paré, Boulogne, France
CH Lyon Sud, Pierre Bénite, France
Chu Trousseau, Tours, France
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.